|
Saturday, May 12, 2012 7:52 AM
|
Ken Torbert
| |
FDA warns of potential danger in MS treatment
The News Journal (blog)
The procedure is known as liberation therapy or liberation procedure and is conducted to treat cerebrospinal venous insufficiency (CCSVI), according to an FDA news annoucement. Some researchers believe that CCSVI – characterized by a narrowing of neck ...
See all stories on this topic » |
FDA Issues Warning On Unproven MS Treatment
Medical News Today
An avante garde procedure used to treat suffers of chronic cerebrospinal venous insufficiency (CCSVI), has been deemed unsafe, causing potential injury and even death. The procedure, known as liberation therapy or liberation procedure, uses stents, ...
See all stories on this topic » |
Vascular Expert Supports FDA Warning about Experimental Therapy for MS Patients
MarketWatch (press release)
Some researchers believe that CCSVI, distinguished by a narrowing of veins in the neck and chest, either may cause or contribute to MS by blocking blood flow from the brain and upper spinal cord. The FDA warned researchers who use balloon angioplasty ...
See all stories on this topic » |
|
Injuries, deaths linked to MS therapy
TheChronicleHerald.ca
Zamboni calls the condition chronic cerebrospinal venous insufficiency, or CCSVI. His treatment uses balloon angioplasty to open up the veins, in the same way coronary arteries narrowed by plaque are unblocked. But unlike Zamboni, some doctors doing ...
See all stories on this topic » |
FDA warns MS patients about risky treatment
Chicago Tribune
Other scientists have not been able to show a link between MS and compromised blood flow, which is called chronic cerebrospinal venous insufficiency, or CCSVI, or prove the condition exists at all. Meanwhile, MS patients seek new treatments, ...
See all stories on this topic » |
|
|